Seattle Genova is working on assisting our clients to develop and test new mRNA vaccines for a wide range of diseases. We are your trusted partner to develop, produce and validate your mRNA-based vaccines with speed at every stage of the development process – from discovery to large scale production. We produce mRNA-based vaccines and provide tailored synthesis at milligram to multigram scales, with lengths ranging from a few hundred nucleotides to greater than 10 kilobases.
mRNA based vaccines are generally classified as either conventional, nonreplicating, or self-replicating (self-amplifying). Nonreplicating mRNA constructs are small in size, simple, and lack additional encoded proteins capable of inducing unintentional immune responses. They encode the immunogen of interest, which is flanked by 5′ and 3′ untranslated regions (UTRs), a 5’ cap structure consisting of 7-methylguanosine (m7G) connected by a triphosphate bridge to the first nucleotide, and a 3′-poly(A) tail. The 5′ m7G cap blocks recognition by the cytoplasmic RNA sensor, RNA helicases retinoic acid-inducible gene I (RIG-I), suppresses 5′–3′ exonuclease-mediated degradation, recruits translation initiation factors, and promotes efficient translation. The length, structure, and regulatory elements within both the 5′ and 3′ UTR regions also contribute to maximum gene expression. The poly(A) tail and its length are critical for translation and protection of the mRNA vaccine construct from degradation.
Advantages of mRNA vaccines
mRNA-based vaccines exhibit a number of potential advantages relative to conventional vaccines, namely they
(1) involve neither infectious elements nor a risk of stable integration into the host cell genome.
(2) generate humoral and cell-mediated immunity.
(3) are well-tolerated by healthy individuals.
(4) are less expensive and produced more rapidly by processes that are readily standardized and scaled-up, improving responsiveness to large emerging outbreaks.
Our service portfolio
In vitro mRNA transcription
DNA template digestion
In-depth analytical characterization and criteria defined for purity/impurity monitoring (CQAs) is needed to ensure safety and efficacy. This means impurities need to be understood through characterization, acceptable levels defined, and then monitored for safety and efficacy. What we are offering for Mrna QCs:
Identity by sequencing
Residual plasmid DNA content
Residual protein content
Poly-A tail length
mRNA content (mg/mL)
mRNA integrity %
With our technology, we are revolutionizing vaccines and developing potential mRNA vaccines in shorter periods of time for previously untreatable and emerging diseases.
Thank you for your interest in our MRNA Based Vaccine Development services. Please complete the form below and we will contact you shortly.
Fields indicated by an * are required.